The bipartisan SHOP SAFE Act of 2020 would require e-commerce platforms to vet and obtain compliance commitments from third-party sellers, include their identities and business information on-site, and block continued access by repeat trademark infringers. The US House bill is backed by the Personal Care Products Council, which cites weaknesses in the current system that allow illicit trade to flourish.
A bipartisan US House bill to hold e-commerce platforms accountable for third-party sales of counterfeit products has the support of the cosmetics industry, which maintains that knock-offs hurt legitimate businesses and endanger consumer health and safety.
Companies’ options in the US are limited, costly and often ineffective when it comes to enforcing their rights against counterfeit...
Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.
Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.
Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.
